Abstract
Gefitinib and erlotinib are both selective EGFR tyrosine kinase inhibitors (EGFR-TKIs) that have produced responses in a small subgroup of lung cancer patients. The strongest evidence for a role of EGFR in the biology of glioblastoma stems from clinical trials in which 15–20% of recurrent glioblastoma patients experienced significant tumour regression in response to these small-molecule EGFR kinase inhibitors. We examined the protein-kinase domain of the EGFR gene, EGFR protein expression and EGFR gene amplification in 20 cases of recurrent GBMs. EGFR protein over-expression was found in 65% of cases. EGFR protein over-expression was associated with EGFR gene amplification in 35% of cases, and with high polysomy in 15% of cases. No mutations were found in the TK domain of the EGFR gene. Our results confirm that mutations in the kinase domain are absent in recurrent GBM, and this might be a preponderant factor in the lack of major clinical responses of TKIs in GBM, recent studies have suggested that responsiveness to EGFR kinase inhibitors was strongly associated with coexpression of EGFRvIII and PTEN. Further prospective validation of EGFRvIII and PTEN as predictors of the clinical response to EGFR kinase inhibitors in recurrent GBM is strongly anticipated.
Similar content being viewed by others
References
Bruner JM (1994) Neuropathology of malignant gliomas. Semin Oncol 21(2):126–138
Gilbert MR, Loghin M (2005) The treatment of malignant gliomas. Curr Treat Options Neurol 7(4):293–303
Rich JN, Hans C, Jones B et al. (2005) Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res. 65(10): 4051–4058
Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37(suppl 4):S9–S15
Lynch TJ, Bell DW, SordellaR et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139
Paez JG, Janne PA, Lee JC et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500
Nathoo N, Goldlust S, Vogelbaum MA (2004) Epidermal growth factor receptor antagonists: novel therapy for the treatment of high-grade gliomas. Neurosurgery 54:1480–1488
Barber TD, Vogelstein B, Kinzler KW et al. (2004) Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 351:2883–2883
Kris MG, Natale RB, Herbst RS et al. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149–2158
Fukuoka M, Yano S, Giaccone G et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21:2237–2246
Mellinghoff IK, Wang MY, Vivanco I et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012–2024
Rich JN, Reardon DA, Peery T et al. (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133–142
Li B, Chang CM, Yuan M et al. (2003) Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res 63:7443–7450
Rich JN, Rasheed BK, Yan H (2004) EGFR mutations and sensitivity to gefitinib. N Engl J Med 351:1260–1261
Aldape KD, Ballman K, Furth A et al. (2004) Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 63:700–707
De Pas T, Pelosi P, de Braud F et al. (2004) Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare. J Clin Oncol 22:4966–4970
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Toth, J., Egervari, K., Klekner, A. et al. Analysis of EGFR Gene Amplification, Protein Over-expression and Tyrosine Kinase Domain Mutation in Recurrent Glioblastoma. Pathol. Oncol. Res. 15, 225–229 (2009). https://doi.org/10.1007/s12253-008-9082-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12253-008-9082-4